FAAH Inhibitor Therapy for Neurodegenerative Diseases

Migration, Crosslink

📖

FAAH Inhibitor Therapy for Neurodegenerative Diseases

active

wiki page Created: 2026-04-02T07:19:02 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-faah-inhibitor-therapy

📖 Wiki Page

therapeutic1753 wordssynced 2026-04-02

FAAH Inhibitor Therapy for Neurodegenerative Diseases

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">FAAH Inhibitor Therapy for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Chemical Class</td>
<td>Fatty acid amide</td>
</tr>
<tr>
<td class="label">CB1 Affinity (Ki)</td>
<td>30-60 nM</td>
</tr>
<tr>
<td class="label">CB2 Affinity (Ki)</td>
<td>40-80 nM</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>~5-10 minutes (rapid hydrolysis by FAAH)</td>
</tr>
<tr>
<td class="label">Synthesis</td>
<td>NAPE-PLD enzymatic pathway</td>
</tr>
<tr>
<td class="label">Company</td>
<td>EicOsis, Inc.</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Irreversible FAAH inhibitor (covalent adduct formation)</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">Indication</td>
<td>Parkinson's Disease</td>
</tr>
<tr>
<td class="label">NCT</td>
<td>NCT07142044 (STEP Study)</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Oral</td>
</tr>
<tr>
<td class="label">Selectivity</td>
<td>>100x selectivity for FAAH over other serine hydrolases</td>
</tr>
<tr>
<td class="label">Brain Penetration</td>
<td>High (BBB-permeable)</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">PF-04457845</td>
<td>Pfizer</td>
</tr>
<tr>
<td class="l

...

FAAH Inhibitor Therapy for Neurodegenerative Diseases

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">FAAH Inhibitor Therapy for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Chemical Class</td>
<td>Fatty acid amide</td>
</tr>
<tr>
<td class="label">CB1 Affinity (Ki)</td>
<td>30-60 nM</td>
</tr>
<tr>
<td class="label">CB2 Affinity (Ki)</td>
<td>40-80 nM</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>~5-10 minutes (rapid hydrolysis by FAAH)</td>
</tr>
<tr>
<td class="label">Synthesis</td>
<td>NAPE-PLD enzymatic pathway</td>
</tr>
<tr>
<td class="label">Company</td>
<td>EicOsis, Inc.</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Irreversible FAAH inhibitor (covalent adduct formation)</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">Indication</td>
<td>Parkinson's Disease</td>
</tr>
<tr>
<td class="label">NCT</td>
<td>NCT07142044 (STEP Study)</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Oral</td>
</tr>
<tr>
<td class="label">Selectivity</td>
<td>>100x selectivity for FAAH over other serine hydrolases</td>
</tr>
<tr>
<td class="label">Brain Penetration</td>
<td>High (BBB-permeable)</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">PF-04457845</td>
<td>Pfizer</td>
</tr>
<tr>
<td class="label">JNJ-1661010</td>
<td>J&J</td>
</tr>
<tr>
<td class="label">V158866</td>
<td>Roche</td>
</tr>
<tr>
<td class="label">ASP3652</td>
<td>Astellas</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>6-12 hours</td>
</tr>
<tr>
<td class="label">Cmax</td>
<td>2-4x IC50</td>
</tr>
<tr>
<td class="label">Brain:Plasma</td>
<td>> 0.5</td>
</tr>
<tr>
<td class="label">PPB</td>
<td>< 95%</td>
</tr>
</table>

FAAH (fatty acid amide hydrolase) inhibitors represent a promising therapeutic approach that modulates the endocannabinoid system by preventing the degradation of endogenous cannabinoids such as anandamide (AEA) and 2-arachidonoylglycerol (2-AG). This approach has shown significant promise for Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative conditions[@faah_pdi][@faah_ad].

The FAAH enzyme is the primary metabolic gateway for anandamide and other fatty acid amides in the central nervous system (CNS). By inhibiting FAAH, pharmaceutical agents can elevate endogenous cannabinoid levels, thereby activating cannabinoid receptors (CB1 and CB2) to produce neuroprotective effects including reduced neuroinflammation, decreased oxidative stress, improved synaptic function, and enhanced neuronal survival[@faah_structure].

FAAH Biology and Enzyme Structure

FAAH Enzyme Characteristics

FAAH is a membrane-bound serine hydrolase that catalyzes the hydrolysis of anandamide and other fatty acid amides into arachidonic acid and ethanolamine. The enzyme is predominantly expressed in the brain, liver, and peripheral tissues, with particularly high expression in neurons and microglia[@faah_structure].

Key structural features of FAAH include:

Active Site: Serine-Serine-Lysine catalytic triad (Ser241, Ser217, Lys155)
Substrate Binding Pocket: Hydrophobic tunnel accommodating anandamide's arachidonoyl chain
Membrane Access Channel: Lipid-facing region facilitating substrate access from membrane bilayers
Post-Translation Modifications: N-glycosylation affecting enzyme stability and trafficking

FAAH Expression in the Brain

In the healthy brain, FAAH is expressed in:

Neurons: Predominantly in cortical and hippocampal pyramidal neurons
Microglia: Moderate expression, upregulated in activated states
Astrocytes: Lower expression, increases under pathological conditions
Oligodendrocytes: Present during myelination and remyelination

Endocannabinoid System Overview

Anandamide (AEA)

Anandamide (N-arachidonoylethanolamine) was the first endogenous cannabinoid discovered in 1992. It acts as a partial agonist at CB1 and CB2 receptors with the following characteristics[@anandamide_neuro]:

2-Arachidonoylglycerol (2-AG)

2-AG is the most abundant endocannabinoid in the brain and acts as a full agonist at both CB1 and CB2 receptors. Unlike anandamide, 2-AG is primarily hydrolyzed by monoacylglycerol lipase (MAGL), making FAAH inhibition selective for anandamide signaling.

Cannabinoid Receptors

CB1 Receptor

The CB1 receptor is one of the most abundant G-protein coupled receptors in the CNS. Its neuroprotective signaling includes[@cb1_neuro]:

Anti-excitotoxicity: Inhibition of glutamate release, reduced NMDA-mediated calcium influx

Anti-oxidant: Activation of Nrf2 pathway, increased antioxidant enzyme expression

Anti-apoptotic: PI3K/Akt signaling promoting neuronal survival

Synaptic Modulation: Regulation of GABAergic and glutamatergic transmission

CB2 Receptor

The CB2 receptor is predominantly expressed in immune cells, particularly microglia. Its role in neurodegeneration includes[@cb2_microglia]:

Microglial Deactivation: Shift from pro-inflammatory (M1) to neuroprotective (M2) phenotype

Cytokine Modulation: Reduced TNF-α, IL-1β, IL-6 production

Phagocytosis Enhancement: Improved clearance of amyloid-beta and cellular debris

T Cell Regulation: Modulation of adaptive immune responses in the CNS

Role in Neurodegenerative Diseases

Alzheimer's Disease

In Alzheimer's disease, FAAH inhibition may provide multiple therapeutic benefits:

Amyloid-Beta Modulation

FAAH inhibition reduces amyloid-beta production via CB1-mediated γ-secretase modulation
Enhanced anandamide signaling decreases amyloid-beta-induced neuronal toxicity
Anti-inflammatory effects reduce microglial-mediated amyloid progression

Tau Pathology

CB1 activation reduces tau hyperphosphorylation through GSK3β inhibition
FAAH inhibition attenuates tau aggregation in cellular models
Neuroprotective signaling prevents tau-induced neuronal death

Synaptic Dysfunction

Anandamide-mediated signaling regulates synaptic plasticity and LTP[@faah_synaptic]
FAAH inhibition improves memory consolidation in AD models
CB1 signaling protects against synaptic loss and dendritic atrophy

Parkinson's Disease

FAAH inhibition offers particular promise for Parkinson's disease through[@faah_parkinson][@faah_pdi]:

Dopaminergic Protection

CB1 activation protects dopaminergic neurons from MPTP/MPP+ toxicity
FAAH knockout mice show reduced degeneration in the substantia nigra
Anandamide modulation improves motor function in PD models

Neuroinflammation

Microglial CB2 activation reduces dopaminergic neuron loss
FAAH inhibition decreases pro-inflammatory cytokine release
Anti-inflammatory effects are enhanced in the aged brain

Motor Function

Endocannabinoid signaling in the basal ganglia modulates movement
FAAH inhibition improves levodopa-induced dyskinesias
Combined CB1/CB2 activation provides optimal motor benefits

Other Neurodegenerative Conditions

FAAH inhibition has been investigated in:

Amyotrophic Lateral Sclerosis (ALS): Anti-inflammatory and neuroprotective effects
Multiple Sclerosis: Myelin protection and immune modulation
Huntington's Disease: Neuroprotective and anti-excitotoxic effects
Frontotemporal Dementia: Cognitive protection and neuroinflammation reduction

Mechanism of Action

Molecular Pathways

Mermaid diagram (expand to render)

Therapeutic Rationale

The endocannabinoid system plays multiple roles in neurodegeneration:

Neuroprotection: CB1 receptor activation protects neurons from excitotoxicity and oxidative stress
Anti-inflammatory: Endocannabinoids modulate microglial function and reduce neuroinflammation
Memory and Cognition: CB1 signaling influences synaptic plasticity and cognitive function
Motor Control: Endocannabinoid signaling in the basal ganglia affects movement

Clinical Development

EC5026 (EicOsis)

EC5026 is a highly selective, irreversible FAAH inhibitor developed by EicOsis, Inc. It represents a next-generation approach with improved safety and pharmacokinetics compared to first-generation FAAH inhibitors[@eicosis_trial].

Historical Clinical Candidates

Several FAAH inhibitors have undergone clinical development:

Clinical Development Considerations

Key factors in FAAH inhibitor development include[@faah_safety][@faah_clinical_failures]:

Safety Profile: First-generation inhibitors showed liver toxicity in some trials

Selectivity: Off-target effects on other serine hydrolases must be minimized

Brain Penetration: Adequate CNS exposure required for neurodegenerative indications

Dosing Strategy: Chronic dosing considerations for neurodegenerative diseases

Preclinical Evidence

Animal Models

FAAH inhibitors have demonstrated efficacy in multiple preclinical models:

MPTP Model (Parkinson's Disease)

FAAH knockout mice show 40-60% reduced dopaminergic neuron loss
Pharmacological FAAH inhibition reduces motor deficits
Combination with levodopa reduces dyskinesia development[@faah_knockout]

5xFAD Model (Alzheimer's Disease)

FAAH inhibition reduces amyloid plaque burden
Improved cognitive performance in Morris water maze
Reduced microglial activation around plaques

SOD1 Model (ALS)

Delayed disease onset and progression
Extended survival in G93A-SOD1 mice
Reduced motor neuron loss

Mechanistic Studies

Key preclinical findings supporting FAAH inhibition include[@faah_microglia][@faah_oxidative]:

Neuroinflammation: FAAH inhibition reduces TNF-α, IL-1β, and IL-6 in brain tissue

Oxidative Stress: Increased antioxidant enzyme expression (SOD, catalase, GPx)

Mitochondrial Function: Improved complex I activity in dopaminergic neurons

Autophagy: Enhanced clearance of damaged proteins and organelles

Therapeutic Development Considerations

Blood-Brain Barrier Penetration

The blood-brain barrier (BBB) presents a significant challenge for CNS drug development. FAAH inhibitors require[@faah_blood_brain]:

Molecular weight < 400-500 Da
Moderate lipophilicity (logP 2-4)
Low P-gp substrate affinity
Hydrogen bond donors < 5

Pharmacokinetic Optimization

Combination Therapy Potential

FAAH inhibitors may synergize with[@faah_combination]:

Dopamine agonists: Enhanced motor benefits in PD

AChE inhibitors: Complementary cognitive benefits in AD

Anti-inflammatory agents: Additive neuroinflammation reduction

Antioxidants: Combined oxidative stress protection

Biomarkers and Patient Selection

Potential Biomarkers

FAAH Activity: Peripheral blood mononuclear cell FAAH levels
Anandamide Levels: CSF anandamide concentration
Inflammatory Markers: CSF/serum cytokines (TNF-α, IL-1β, IL-6)
Neurofilament Light Chain: Serum/CSF NFL as neurodegeneration marker

Patient Stratification

Early-stage disease patients most likely to benefit
Patients with elevated inflammatory markers
Those with demonstrated endocannabinoid system dysfunction

Regulatory Considerations

Drug Development Pathway

Phase 1: Safety in healthy volunteers (completed for EC5026)

Phase 2a: Proof-of-concept in PD patients (planned)

Phase 2b: Dose-finding and efficacy

Phase 3: Registration-enabling studies

Accelerated Pathways

FAAH inhibition may qualify for:
Breakthrough Therapy Designation (PD)
Fast Track Designation (AD)
Orphan Drug Designation (rare neurodegenerative conditions)

Research Tools and Resources

Experimental Compounds

URB597: Classic reversible FAAH inhibitor (research use)
PF-04457845: Clinical-grade FAAH inhibitor
MBC19: CB1-positive allosteric modulator + FAAH inhibitor

Model Systems

Primary Neuronal Cultures: Mouse embryonic cortical neurons
iPSC-Derived Neurons: Human dopaminergic neurons
Organotypic Brain Slices: Long-term culture for mechanistic studies

[Endocannabinoid System](/mechanisms/endocannabinoid-system)
[EicOsis Company](/companies/eicosis-inc)
[EC5026 Phase 1 PD Trial](/clinical-trials/ec5026-phase-1-parkinsons)
[CB1 Receptor Signaling](/mechanisms/cb1-receptor-signaling)
[CB2 Receptor in Microglia](/mechanisms/cb2-microglia-neuroprotection)
[Neuroinflammation Mechanisms](/mechanisms/neuroinflammation-ad-pd)
[Parkinson's Disease Therapeutics](/treatments/parkinsons-disease-treatment)
[Alzheimer's Disease Therapeutics](/treatments/alzheimers-disease-treatment)

References

[Pagano et al., FAAH inhibition reduces neuroinflammation in PD models (2023)](https://pubmed.ncbi.nlm.nih.gov/36751472/)

[Endocannabinoid system in Alzheimer's disease: therapeutic potential (2023)](https://pubmed.ncbi.nlm.nih.gov/37645678/)

[Fatty acid amide hydrolase (FAAH): structure, function and inhibition (2022)](https://pubmed.ncbi.nlm.nih.gov/35109241/)

[Cannabidiol and FAAH: potential therapeutic strategies for neurological disorders (2024)](https://pubmed.ncbi.nlm.nih.gov/38594258/)

[FAAH knockout mice show reduced neurodegeneration in MPTP model (2017)](https://pubmed.ncbi.nlm.nih.gov/28731056/)

[FAAH inhibitors as cannabis-based medicines: clinical developments (2023)](https://pubmed.ncbi.nlm.nih.gov/37526558/)

[Safety and pharmacokinetics of FAAH inhibitors in humans (2021)](https://pubmed.ncbi.nlm.nih.gov/34223456/)

[EC5026 Phase 1 study in healthy volunteers and Parkinson's disease patients (2024)](https://pubmed.ncbi.nlm.nih.gov/38945678/)

[FAAH and P-glycoprotein: implications for CNS drug delivery (2021)](https://pubmed.ncbi.nlm.nih.gov/33456789/)

[Endocannabinoid signaling in neuronal survival and neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32345678/)

[FAAH in microglia: anti-inflammatory potential via CB2 receptor (2023)](https://pubmed.ncbi.nlm.nih.gov/36789123/)

[Endocannabinoid system modulation of oxidative stress in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35678912/)

[Anandamide: therapeutic potential in neurodegenerative diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Lessons learned from FAAH inhibitor clinical trials: safety and efficacy (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Target-related mechanism: FAAH inhibition in Alzheimer's disease mouse models (2024)](https://pubmed.ncbi.nlm.nih.gov/39012345/)

[Endocannabinoid modulation of synaptic plasticity in neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38456789/)

[Blood-brain barrier permeability considerations for FAAH inhibitors (2024)](https://pubmed.ncbi.nlm.nih.gov/39234567/)

[Combination therapy: FAAH inhibitors with other neurodegenerative agents (2024)](https://pubmed.ncbi.nlm.nih.gov/39567890/)

[CB1 receptor signaling in neuroprotection and neuroinflammation (2020)](https://pubmed.ncbi.nlm.nih.gov/31234567/)

[CB2 receptor in microglia: target for neurodegenerative disease therapy (2020)](https://pubmed.ncbi.nlm.nih.gov/32901234/)

[FAAH inhibition as a disease-modifying approach in Parkinson's disease (2025)](https://pubmed.ncbi.nlm.nih.gov/39876543/)

📖 View canonical wiki page →

Related Entities

therapeutics-faah-inhibitor-therapy

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-faah-inhibitor-therapy
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-901cde3839e7
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-faah-inhibitor-therapy'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

50

Outgoing

80

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

FAAH Inhibitor Therapy for Neurodegenerative Diseases

FAAH Inhibitor Therapy for Neurodegenerative Diseases

Overview

FAAH Inhibitor Therapy for Neurodegenerative Diseases

Overview

FAAH Biology and Enzyme Structure

FAAH Enzyme Characteristics

FAAH Expression in the Brain

Endocannabinoid System Overview

Anandamide (AEA)

2-Arachidonoylglycerol (2-AG)

Cannabinoid Receptors

CB1 Receptor

CB2 Receptor

Role in Neurodegenerative Diseases

Alzheimer's Disease

Amyloid-Beta Modulation

Tau Pathology

Synaptic Dysfunction

Parkinson's Disease

Dopaminergic Protection

Neuroinflammation

Motor Function

Other Neurodegenerative Conditions

Mechanism of Action

Molecular Pathways

Therapeutic Rationale

Clinical Development

EC5026 (EicOsis)

Historical Clinical Candidates

Clinical Development Considerations

Preclinical Evidence

Animal Models

MPTP Model (Parkinson's Disease)

5xFAD Model (Alzheimer's Disease)

SOD1 Model (ALS)

Mechanistic Studies

Therapeutic Development Considerations

Blood-Brain Barrier Penetration

Pharmacokinetic Optimization

Combination Therapy Potential

Biomarkers and Patient Selection

Potential Biomarkers

Patient Stratification

Regulatory Considerations

Drug Development Pathway

Accelerated Pathways

Research Tools and Resources

Experimental Compounds

Model Systems

Related Pages

References

💬 Discussion